Lab21 acquires Microgen Bioproducts
Lab21 Limited announced that it has acquired Microgen Bioproducts Ltd a UK company specialising in the development, manufacture and sale of diagnostic tests to identify diseases and organisms which pose a threat to health.
Microgen Bioproducts’ expertise in microbiological assay development and commercialisation complements Lab21’s diagnostics portfolio particularly in the infectious disease market. This transaction provides further expansion of Lab21’s distribution channel in key territories including the US, UK, Europe and Asia.
Graham Mullis, CEO of Lab21 said: “Microgen Bioproducts is a well established and profitable business which will significantly contribute to our growth plans in our core products division. This acquisition highlights Lab21’s commitment to continuing its exciting roll-up strategy and we expect to bring other high quality acquisitions into the Group during 2011.”
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Injection_(medicine)
UMDNJ-School_of_Osteopathic_Medicine
Category:Hypholoma
Category:Fungi_found_in_fairy_rings
Ocular_oncology

PFAS influence the development and function of the brain - Study uncovers mechanism of action with new test method

Scientists engineer new potent antibiotic - Darobactin 22 could have the potential to become the next antibiotic superstar
